<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/7A548FB1-2906-495F-9C5E-59F0EE55EF4A"><gtr:id>7A548FB1-2906-495F-9C5E-59F0EE55EF4A</gtr:id><gtr:name>Mathematical, Physical &amp; Life Sciences Division</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3B4CD670-EFA7-4A29-8208-6EE0C7AE6545"><gtr:id>3B4CD670-EFA7-4A29-8208-6EE0C7AE6545</gtr:id><gtr:name>Shire Pharmaceuticals</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/BC0E951E-239C-4369-8E5A-6E82F9B06B50"><gtr:id>BC0E951E-239C-4369-8E5A-6E82F9B06B50</gtr:id><gtr:name>University of Leiden</gtr:name><gtr:address><gtr:line1>P.O. Box 9506</gtr:line1><gtr:line4>Leiden</gtr:line4><gtr:line5>2300</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Physiology Anatomy and Genetics</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/7A548FB1-2906-495F-9C5E-59F0EE55EF4A"><gtr:id>7A548FB1-2906-495F-9C5E-59F0EE55EF4A</gtr:id><gtr:name>Mathematical, Physical &amp; Life Sciences Division</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3B4CD670-EFA7-4A29-8208-6EE0C7AE6545"><gtr:id>3B4CD670-EFA7-4A29-8208-6EE0C7AE6545</gtr:id><gtr:name>Shire Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/BC0E951E-239C-4369-8E5A-6E82F9B06B50"><gtr:id>BC0E951E-239C-4369-8E5A-6E82F9B06B50</gtr:id><gtr:name>University of Leiden</gtr:name><gtr:address><gtr:line1>P.O. Box 9506</gtr:line1><gtr:line4>Leiden</gtr:line4><gtr:line5>2300</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/95DF1C05-09A0-412A-87F2-6D0A6175BFD7"><gtr:id>95DF1C05-09A0-412A-87F2-6D0A6175BFD7</gtr:id><gtr:firstName>Matthew</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Wood</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E745CA89-5108-4021-A758-26E57AB3F314"><gtr:id>E745CA89-5108-4021-A758-26E57AB3F314</gtr:id><gtr:firstName>Haifang</gtr:firstName><gtr:surname>Yin</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0900887"><gtr:id>7BD85859-8D7D-4DA7-906E-6FB697E05543</gtr:id><gtr:title>Antisense nucleic acid splice correction therapy for Duchenne muscular dystrophy and related disorders</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0900887</gtr:grantReference><gtr:abstractText>Degenerative diseases cause increasing medical and social burdens in aging Western societies. Few of these diseases are treatable and therefore it is vital that new types of therapies are developed. In this research we will study Duchenne muscular dystrophy (DMD), a common, X-linked inherited, degenerative disease of muscle caused by lack of the protein dystrophin, and that is uniformly fatal and currently untreatable, typically leading to the deaths of affected boys in their 20s. We will investigate a new type of gene therapy for DMD, which has already shown promise in two preliminary clinical trials in DMD patients. The therapy, called exon skipping, uses small DNA patches known as antisense oligonucleotides (AOs) to correct the effects of mutations in the dystrophin gene, thereby producing new dystrophin protein of near-normal function and correcting the harmful effects of the disease. The recent clinical trials tested the application of this method in single muscles and therefore one of the major challenges in taking this therapy forward is to develop the means to deliver the AOs effectively to all muscle groups and also to the heart, given that all are affected by the disease. We have recently discovered that attaching small protein fragments known as peptides to the AO allows greatly improved delivery of the AO compounds to multiple muscle groups and heart. In this research we now also plan to test protein fragments that potentially allow the AO to be targeted specifically to muscle and /or heart, initially studying a recently discovered prototype compound known as B-MSP-PMO. We plan to test its long-term effectiveness in two mouse models of DMD, one mild and one severe, and also to attempt to understand better how this compound is targeted to muscle and to what extent it is likely to be safe to use. We also plan to evaluate improved versions of this AO as we are currently working to discover improved peptides that may target the AO to muscle and or heart with even greater efficiency. We will also investigate further recent exciting findings where we have discovered that the delivery of such drugs can be enhanced further by administering them together with a range of sugars. This work will therefore significantly advance the prospects for a disease-modifying therapy for DMD and also for other diseases where exon skipping or AO delivery would be a valuable therapy.</gtr:abstractText><gtr:technicalSummary>Experimental nucleic acid based therapies are being intensively investigated as novel strategies for currently untreatable human disease. This Programme aims to develop a detailed molecular understanding of the chemical biological requirements for long-term, targeted, functional and phenotypic antisense oligonucleotide (AO)-mediated splice correction in mouse models of Duchenne muscular dystrophy (DMD). DMD is a fatal muscle degenerative disease and AO mediated splice correction of the DMD pre-mRNA has the potential to treat approximately 75% of DMD patients and has been shown to be well tolerated with therapeutic efficacy in two recent Phase I clinical trials. A critical challenge now in the development of this approach is the need for long-term, targeted, high efficiency systemic correction of the DMD phenotype. In this Programme beginning with state-of-the-art AO-peptide conjugates (B-PMO and B-MSP-PMO) we will study long-term correction of the muscle and cardiac physiological phenotypes following splice correction in dystrophin deficient mdx and dystrophin/utrophin deficient double knockout (DKO) mice. We will also discover and study novel transduction peptides for enhanced AO delivery and splice correction, and develop methods for targeted AO delivery to muscle and cardiac tissues including novel chimeric transduction/targeting peptides and study their mechanisms of action. AO conjugates incorporating these novel peptides will be studied over the long term in DMD animal models. Work will further include study of safety aspects including long term toxicology, tissue biodistribution/pharmacokinetics, and genome-wide off-target and splicing dysregulation effects. Finally, we will further investigate our striking recent findings related to GLUT transporter mediated AO delivery to muscle and cardiac tissues. This is a challenging and integrated programme of work with several streams of study moving from discovery and basic chemistry and chemical biology through to in vitro and in vivo studies in DMD animal models and clinical application via the PI?s participation in the UK MDEX Consortium. It will substantially advance our understanding of the requirements for successful systemic splice correction of the DMD phenotype and will have direct implications for the therapy of related neuromuscular disorders and other diseases where forced manipulation of pre-mRNA splicing and/or targeted AO delivery would be of therapeutic value.</gtr:technicalSummary><gtr:fund><gtr:end>2016-08-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1500712</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Human Genetics; Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Cardiac aspects of neuromuscular disease</gtr:description><gtr:id>2A653BFE-195A-438C-8928-2A44CCD25153</gtr:id><gtr:impact>n / a</gtr:impact><gtr:partnerContribution>Physiological analysis</gtr:partnerContribution><gtr:piContribution>Stiudy of cardiac aspects of neuromuscular disease - expertise and materials</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Laboratory of Molecular Biology</gtr:department><gtr:description>Development of Cell Penetrating Peptides</gtr:description><gtr:id>2841F3EA-1A9A-4F0B-9226-E6D7C7E93B33</gtr:id><gtr:impact>Several papers and IPs have resulted from this collaboration in the field of Duchenne muscular dystrophy.</gtr:impact><gtr:partnerContribution>Development of novel cell penetrating peptides for the purposes of delivering antisense oligonucleotides.</gtr:partnerContribution><gtr:piContribution>We provide in vivo analysis of novel cell penetrating peptides.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leiden University</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Leiden University Partnership</gtr:description><gtr:id>66AE0CA0-08DE-4DE2-8A1C-04E1C92DA03C</gtr:id><gtr:impact>not yet</gtr:impact><gtr:partnerContribution>In vivo analysis of exon skipping drugs in humanised mouse model of DMD</gtr:partnerContribution><gtr:piContribution>Provided materials for study in transgenic mouse model of DMD</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Oxford Stem Cell Institute</gtr:department><gtr:description>Oxford Stem Cell Institute</gtr:description><gtr:id>2C61D5C9-6BF2-48AC-AEFE-0E3A999FA397</gtr:id><gtr:impact>n/a</gtr:impact><gtr:partnerContribution>Stem cell expertise and materials</gtr:partnerContribution><gtr:piContribution>RNA biology / technology</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karolinska Institute</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Karolinska partnership</gtr:description><gtr:id>3A8446E7-B0C5-4293-B37D-F3A7643EF475</gtr:id><gtr:impact>Roberts et al. Molecular Therapy Nucleic Acids 2012</gtr:impact><gtr:partnerContribution>Undertaking first stage transcriptomic and proteomic analysis</gtr:partnerContribution><gtr:piContribution>Experimental design and material for transcriptomic and proteomic analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Functional Genomics Unit</gtr:department><gtr:description>Muscular dystrophy biology</gtr:description><gtr:id>877E1FE6-0170-4FEF-A742-C23BB13E00D7</gtr:id><gtr:impact>Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches.

Fairclough RJ, Wood MJ, Davies KE.

Nat Rev Genet. 2013 Jun;14(6):373-8</gtr:impact><gtr:partnerContribution>Expertise and materials</gtr:partnerContribution><gtr:piContribution>Expertise and materials</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Laboratory of Molecular Biology (LMB)</gtr:department><gtr:description>Gait collaboration</gtr:description><gtr:id>FD33D6BF-AF0E-412E-A3F9-EFEE4F28DA86</gtr:id><gtr:impact>18776238 
21062902
20068555
18842625</gtr:impact><gtr:partnerContribution>Materials</gtr:partnerContribution><gtr:piContribution>In vivo work, miRNA work, oligonucleotide work</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL), MRC Centre for Neuromuscular Disease</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC Neuromuscular centre, UCL</gtr:description><gtr:id>07E7AC7C-AD7B-4BA2-8B3E-0353F49B32E7</gtr:id><gtr:impact>Collaboration and joint research programmes</gtr:impact><gtr:partnerContribution>Clinical material and stem cell expertise</gtr:partnerContribution><gtr:piContribution>Therapy development for neuromuscular disease</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Institutes for Biomedical Research</gtr:department><gtr:description>Novartis</gtr:description><gtr:id>146F7646-2183-4CF3-9532-534BA6C704A9</gtr:id><gtr:impact>n/a</gtr:impact><gtr:partnerContribution>RNA technology</gtr:partnerContribution><gtr:piContribution>Parkinson's disease expertise</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Shire Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>Shire Partnership</gtr:description><gtr:id>70F9F1FA-0AD6-49C6-8E94-21C4A916996E</gtr:id><gtr:impact>None yet</gtr:impact><gtr:partnerContribution>Expertise in oligonucleotide synthesis and toxicology</gtr:partnerContribution><gtr:piContribution>Expertise in antisense oligonucleotides for neuromuscular disease</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mathematical, Physical &amp; Life Sciences Division</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Physics; University of Oxford</gtr:department><gtr:description>PHYSICS OXFORD</gtr:description><gtr:id>3F1094C6-C268-4160-94ED-F70E5228EAB2</gtr:id><gtr:impact>WALSH ET AL. ACS NANO 2011</gtr:impact><gtr:partnerContribution>NOVEL METHODS OF DNA/OLIGONUCLEOTIDE DELIVERY</gtr:partnerContribution><gtr:piContribution>INTELLECTUAL INPUT
CELL LINES AND ANIMAL MODELS
EXPERIMENTAL DESIGN</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Institute of Child Health</gtr:department><gtr:description>MDEX CONSORTIUM</gtr:description><gtr:id>836A0B81-0309-4508-9240-6BDA1A931EEB</gtr:id><gtr:impact>19713152</gtr:impact><gtr:partnerContribution>New avenues for experimental work</gtr:partnerContribution><gtr:piContribution>Pre-clinical evaluation of oligonucleotides for muscular dystrophy therapy</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MDA conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6053C6DC-49E1-47FF-8702-EE226404D1C8</gtr:id><gtr:impact>public engagement

education and policy</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Parent Project Muscular Dystrophy's Annual Connect Conference</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>46AA646D-5198-4A0C-9F82-A4E8A5CB6E11</gtr:id><gtr:impact>Attended the Parent Project Muscular Dystrophy's Annual Connect Conference in Orlando</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Muscular Dystrophy UK</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F7884D60-84AC-4220-8C8B-C530E49E1DA5</gtr:id><gtr:impact>Often invited to visit parent/patient meetings to chat</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>New Directions in Biology and Disease of Skeletal Muscle meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0D64C824-B2FF-47BC-94FF-F9600AEE6AC7</gtr:id><gtr:impact>Spoke at the New Directions in Biology and Disease of Skeletal Muscle meeting in Orlando</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC INTERVIEWS</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0FD837BD-8EBE-418D-9A49-651319D33DAE</gtr:id><gtr:impact>BBC TV INTERVIEW

NUMEROUS OFFERS TO WRITE ABOUT AND TALK ABOUT OUR WORK</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oligonucleotide Therapeutics Society 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6FB1AAD2-33E3-4F67-A7CF-19CEF90F2E00</gtr:id><gtr:impact>Poster Presentation: &amp;quot;A new non-base chemical modifier &amp;quot;ZEN&amp;quot; enhances efficacy of splice-switching oligonucleotides&amp;quot;</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International congress of myology</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>56C653FF-DB9C-457C-8F06-0C8405BEE785</gtr:id><gtr:impact>Poster Presentation :Development of a cell-penetrating peptide for the delivery of antisense oligonucleotides to peripheral and CNS tissues of spinal muscular atrophy mice</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Families of Spinal Muscular Atrophy Conference 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DB1D9531-111A-42F1-8798-63C0ABE24845</gtr:id><gtr:impact>Poster Presentation &amp;quot;Peptide delivery of splice switching oligonucleotides for the treatment of SMA &amp;quot;</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MDC NEWSLETTER</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>FCEF31C2-8099-42D3-AC8E-6B19A4FCC7FD</gtr:id><gtr:impact>SHORT NEWS ARTICLE

INVITATIONS TO TALK ABOUT WORK</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oligonucleotide Therapeutics Society 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5B838365-057E-4C00-8C6B-8D19E70CFA7B</gtr:id><gtr:impact>Poster Presentation &amp;quot;NOVEL CELL PENETRATING PEPTIDES FOR SKELETAL AND CARDIAC MUSCLE DELIVERY OF PMO ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY&amp;quot;</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oligonucleotide Delivery: Biology, Engineering and Development Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C13ECE88-729B-4E60-90B3-43BA8EA241AD</gtr:id><gtr:impact>Presentation entitled &amp;quot;A new non-base chemical modifier 'ZEN' enhances efficacy of splice-switching oligonucleotides&amp;quot;.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>http://www.eurekalert.org/pub_releases/2012-06/eci-od062712.php</gtr:url><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Neuroscience School of Advanced Studies (NSAS) forum  - Non-coding RNA in Brain Function and Disorders</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>36A79B98-62CC-4057-B9C3-8066CE2C96D8</gtr:id><gtr:impact>Neuroscience School of Advanced Studies (NSAS) forum 1 day full teaching of Non-coding RNA in Brain Function and Disorders to course members</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MDC Visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>327722B0-9B9D-4628-8FFD-0D44ED3E1F64</gtr:id><gtr:impact>public engagement

education, engagement, patient recruitment</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Action Duchenne Conference 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4F94319F-DF14-431D-A014-64A8DF0C1DB3</gtr:id><gtr:impact>Public engagement

EDUCATION</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public talk/lecture/debate - DMD</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>509A88BF-0E4D-49B1-B666-ADBAC894DB91</gtr:id><gtr:impact>Engage DMD patients, families, carers and the DMD community more generally in thinking about progress in new therapy development and the associcated challenges.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK Neuromuscular Translational Research 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>39C9002C-4FA1-4B06-B02C-94BA5EF6E21F</gtr:id><gtr:impact>Poster presentation :A new non-base chemical modifier &amp;quot;ZEN&amp;quot; enhances efficacy of splice-switching oligonucleotides</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Muscular dystrophy campaign public meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>081D6D83-31FD-4A40-BAFB-212F750453A6</gtr:id><gtr:impact>~100 people attended a public presentation

Funding
Refining research strategy of organisation
Policy discussion</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ACTION DUCHENNE MEETING</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B4F1C041-A2C3-4217-ADD0-412598F85C9B</gtr:id><gtr:impact>150 PE0PLE ATTENDED TALK AND PUBLIC MEETING

REGULAR INPUT TO ORGANISING PATIENT AND FAMILY MEETINGS FOR DUCHENNE PATIENT COMMUNITY TO DISCUSS RESEARCH PROGRESS</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TV broadcast in support of BBC Lifeline Appeal</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CD22D16B-27E8-4DDD-B662-BB56B4527659</gtr:id><gtr:impact>Sue Barker, President of Muscular Dystrophy UK, talks to Professor Wood on BBC Lifeline, 22 March. Muscular Dystrophy UK supports people 
living with these conditions and invests in groundbreaking research.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.musculardystrophyuk.org/app/uploads/2015/03/COMM5-B_-_Lifeline_posters_Prof_Matthew_Wood.pdf</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>A Talk to year 10 students</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>979DA12E-D83D-42FB-8F5E-04C2BD7C5A49</gtr:id><gtr:impact>A talk to year 10 students interested in a career in medical sciences.
The outcome was pupils from the school asking to conduct work experience in the lab.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EU COST Network Workshops</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>68F675BC-F5AE-40F4-ADCC-139C4D9B451A</gtr:id><gtr:impact>Talk: &amp;quot;Enhancing systemic biodistribution of SSOs using peptide delivery: The next step for SSO treatment of SMA&amp;quot;</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TREAT-NMD</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>366B0A28-EB48-4FDB-B027-194BFAABA2D0</gtr:id><gtr:impact>EDUCATION AND POLICY IN RELATION TO NEUROMUSCULAR DISEASE

EDUCATION AND POLICY IN RELATION TO NMD</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009,2011,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1008202</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DPFS - SMA</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>MRC-UK</gtr:fundingOrg><gtr:fundingRef>MR/L013142/1</gtr:fundingRef><gtr:id>A5B793AD-D183-412D-A013-56993301566F</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>IMI EU AWARD</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>DC44B76D-8D85-49D7-83AB-139B80ECD731</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1023000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pfizer</gtr:description><gtr:end>2017-11-02</gtr:end><gtr:fundingOrg>Pfizer Inc</gtr:fundingOrg><gtr:fundingRef>NA</gtr:fundingRef><gtr:id>AC5B2E43-9B18-4C2F-9F8B-7AADD5472D36</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2014-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>WELLCOME TRUST FUNDING</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>FD87AD08-49E5-4F64-BCE9-14251681303B</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>WELLCOME TRUST FUNDING 2</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>9BFB87D5-7FF3-499D-8408-D3014371E1AA</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>82173</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MD UK studentship KM</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Muscular Dystrophy UK</gtr:fundingOrg><gtr:fundingRef>RA3/3031</gtr:fundingRef><gtr:id>4A186D18-ABDE-45D8-A110-B5FEE438A9BD</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NOVARTIS FUNDING</gtr:description><gtr:fundingOrg>Novartis</gtr:fundingOrg><gtr:id>A75753C4-9569-4F1D-9CC8-A079DF0283B0</gtr:id><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>750000</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>AFM NETWORK GRANT FOR MD</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>French Muscular Dystrophy Association (AFM)</gtr:fundingOrg><gtr:id>2AE6225E-06CC-4BAB-803C-89B0A8FC70C9</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Action Duchenne Project Grant</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Action Duchenne</gtr:fundingOrg><gtr:id>08951E29-BF59-4927-A231-ADE103E94CF3</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PARKINSONS UK RESEARCH GRANT</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Parkinson's UK (Parkinson's Disease Society)</gtr:fundingOrg><gtr:id>FFCEF7FA-983D-458A-BAD2-47085437AE05</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MDC Project Grant</gtr:description><gtr:end>2017-01-02</gtr:end><gtr:fundingOrg>Muscular Dystrophy UK</gtr:fundingOrg><gtr:id>D9AF8FA2-A315-47E0-97B9-76ADE22CFF80</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>380000</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>WaVe</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Wave Life Sciences</gtr:fundingOrg><gtr:fundingRef>NA</gtr:fundingRef><gtr:id>7A543E8B-905E-4B05-B92A-81BB5999F5B9</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>110231</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MD UK studentship TVW</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Muscular Dystrophy UK</gtr:fundingOrg><gtr:fundingRef>RA4/3015/2</gtr:fundingRef><gtr:id>9B8EB38F-475D-41FC-8EAD-15AA3BFD19B7</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Parkinson's UK Centre Award</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Parkinson's UK (Parkinson's Disease Society)</gtr:fundingOrg><gtr:id>62EE39DB-8157-4ED4-81A1-2CBF880781D9</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1650000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC PROGRAMME</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>451FB182-2355-4806-8382-399F04B74F2A</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>EXOSOME BASED GENE DELIVERY</gtr:description><gtr:id>5769FB45-DC22-458D-9A8E-0826D9751F8A</gtr:id><gtr:impact>COMMERCIALISATION</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2010119256</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>EXOSOMES</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Novel cell penetrating peptides</gtr:description><gtr:id>E06B9A0A-2BEC-4339-A489-0DE858BA366B</gtr:id><gtr:impact>Funding and joint research programmes</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>US20110130346</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Peptides</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>MIRTRON MEDIATED GENE SILENCING</gtr:description><gtr:id>57851074-56ED-4AB9-AFB1-8234140D7DD6</gtr:id><gtr:impact>COMMERCIALISATION</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>US2011229880</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>MIRTRONS</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Novel cell penetrating peptides</gtr:description><gtr:id>4E4272F1-4ABF-46F4-81AA-51C1894454FE</gtr:id><gtr:impact>Funding and joint collaborative research programmes</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2009147368</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Peptides</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Novel cell penetrating peptides</gtr:description><gtr:id>5FA51F58-F7C7-43DF-8419-3964F308124A</gtr:id><gtr:impact>Funding and joint research programmes</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>GB1115014.1</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Peptides</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Parkinson's UK Advisory Committee</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>A50B6364-F3F4-4ED4-B6B6-4C47A5F6327C</gtr:id><gtr:impact>Research funding and research policy</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>European training network</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>818D3EE6-3CCE-42AA-86E8-F0B454BC4947</gtr:id><gtr:impact>Recognition that better training of scientists and clinicians and muscle disease biology and therapy is necessary</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>European COST award for exosomes</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>171E8881-A490-4D1D-889D-A3A160563FCA</gtr:id><gtr:impact>Training programme for researchers and collaborative network that has been initiated</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EU COST NETWORK WORKSHOPS</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>4A4884E0-0B89-4CA2-A3BF-480BC51F817E</gtr:id><gtr:impact>IMPROVED REGULATION IN RELATION TO DMD CLINICAL TRIALS</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>IDESC</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>3610586F-2853-4635-BF93-0FFFE189B4EE</gtr:id><gtr:impact>INTERNATIONAL NETWORK TO DISSEMINATE THERAPIES FOR NEUROMUSCULAR DISEASE</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Action Duchenne</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>15CBF075-6814-435C-9C79-E64CEE605E58</gtr:id><gtr:impact>Improved funding environment for new treatments for DMD
Discussions wiht regulators re fast track approval of new oligonucleotide therapies for DMD</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>TREAT NMD SYMPOSIUM</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>2E8F7B79-B19F-4A67-89E8-295D78C3A2D7</gtr:id><gtr:impact>IMPROVED CLINICAL TRIAL DESIGN</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>European COST Award for oligonucleotide therapies</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>20AE1010-9B45-4E75-9B5E-258D1B2788D0</gtr:id><gtr:impact>Training programme for researchers and collaborative network that has been initiated</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>TREAT-NMD</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>104DB7C1-27F9-4EF2-BA8B-D7D0BDFBBD9C</gtr:id><gtr:impact>Clinical trials policy for european neuromuscular disease research</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>TREAT NMD</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>0EDB00A4-F1E0-4706-B7FA-9156128F0AE8</gtr:id><gtr:impact>STANDARD OPERATING PROCEDURES AND STANDARDS OF CARE FOR NEUROMUSCULAR DISEASE</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>oligonucleotide exon inclusion therapy for SMA</gtr:description><gtr:id>3ECE2A22-8CD5-4A22-ADF9-2FF76689964B</gtr:id><gtr:impact>early preclinical development of a first in class therapuetic agent</gtr:impact><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>SMA oligonucleotide therapy</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>an exon skipping oligonucleotide product for DMD</gtr:description><gtr:id>C9976157-46A5-4447-A0D4-2CA302F3E5CA</gtr:id><gtr:impact>publication
IP
commercial collaboration</gtr:impact><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>DMD oligonucleotide therapy</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>oligonucleotide exon inclusion therapy for SMA</gtr:description><gtr:id>55342776-07DC-4E49-930B-880D0F77633F</gtr:id><gtr:impact>early preclinical development of novel first in class therapeutic</gtr:impact><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>SMA oligonucleotide therapy</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Novel cell penetrating peptides</gtr:description><gtr:id>6A4C762E-7879-45CA-B160-0DBBB6B7E8E8</gtr:id><gtr:impact>Collaboration and joint research programmes</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Peptides</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>IMPROVED ASSAYS FOR EXTRACELLULAR RNAs</gtr:description><gtr:id>297157F0-CFD1-4636-84E2-EC8487E9459D</gtr:id><gtr:impact>new data in relation to EC RNA
new collaborations in relation to EC RNA
standardisation of EC RNA protocols</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>EXTRACELLULAR RNA METHODS</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Cell targeting peptides</gtr:description><gtr:id>0F357938-56D4-4909-8276-A079BFB1EF55</gtr:id><gtr:impact>Collaboration and joint research programmes</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Peptides</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>improved methods for insertion of RNA cargoes into extracellular vesicles</gtr:description><gtr:id>D12AFC89-DF64-4E02-8EF2-7AF46D2DDF68</gtr:id><gtr:impact>collaboration</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>exosome RNA loading</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>improved exosome isolation and purification methods</gtr:description><gtr:id>C27B4503-23B3-4804-B262-D249486209E8</gtr:id><gtr:impact>dramatically improved ability to analyse different extracellular vesicle populations</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>exosome isolation methods</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>EXOSOME BASED DRUG DELIVERY VEHICLE</gtr:description><gtr:id>F99972F5-BA26-471D-8493-BCC0DCAD90D9</gtr:id><gtr:impact>COMMERCIALISATION</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>EXOSOMES</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6BBBA8C3-AC26-4AE7-97CC-9E0B7C8BC810"><gtr:id>6BBBA8C3-AC26-4AE7-97CC-9E0B7C8BC810</gtr:id><gtr:title>Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f4345298aa80f7aab384e189cb31b897"><gtr:id>f4345298aa80f7aab384e189cb31b897</gtr:id><gtr:otherNames>Kinali M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/48F5F80E-F51E-484A-BC72-CA669D869814"><gtr:id>48F5F80E-F51E-484A-BC72-CA669D869814</gtr:id><gtr:title>Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/58167f6b50117655440b62f734850c9f"><gtr:id>58167f6b50117655440b62f734850c9f</gtr:id><gtr:otherNames>Lehto T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/17A0FD2A-CE5A-4DD5-8810-6D2BE47CC23E"><gtr:id>17A0FD2A-CE5A-4DD5-8810-6D2BE47CC23E</gtr:id><gtr:title>Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/37f48950ac754a3c97a85fecf4e1d7e4"><gtr:id>37f48950ac754a3c97a85fecf4e1d7e4</gtr:id><gtr:otherNames>Coenen-Stass AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9506C63A-87D3-45B2-9742-44745C9D3DB0"><gtr:id>9506C63A-87D3-45B2-9742-44745C9D3DB0</gtr:id><gtr:title>Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/baf93ecbab15b08ce52d70b1af9453dc"><gtr:id>baf93ecbab15b08ce52d70b1af9453dc</gtr:id><gtr:otherNames>Cirak S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/44937DAE-5276-4F25-8298-ABB0DCBFF659"><gtr:id>44937DAE-5276-4F25-8298-ABB0DCBFF659</gtr:id><gtr:title>Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b7bb9ddd1d52e8aedca258b33a5fc54b"><gtr:id>b7bb9ddd1d52e8aedca258b33a5fc54b</gtr:id><gtr:otherNames>Yin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/95D30811-2D13-4F4E-877E-B5644C90F6A9"><gtr:id>95D30811-2D13-4F4E-877E-B5644C90F6A9</gtr:id><gtr:title>Exosomes for targeted siRNA delivery across biological barriers.</gtr:title><gtr:parentPublicationTitle>Advanced drug delivery reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fb14ea7bd67fde0754c86cbfaec1b160"><gtr:id>fb14ea7bd67fde0754c86cbfaec1b160</gtr:id><gtr:otherNames>El Andaloussi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0169-409X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C833BEAF-B726-4FEF-8CD7-BACD576DD468"><gtr:id>C833BEAF-B726-4FEF-8CD7-BACD576DD468</gtr:id><gtr:title>Polyglutamine disease: from pathogenesis to therapy.</gtr:title><gtr:parentPublicationTitle>South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3317ef5032b615cb7a80f92fa1019330"><gtr:id>3317ef5032b615cb7a80f92fa1019330</gtr:id><gtr:otherNames>Watson LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B7F12B52-BF14-41B7-9A90-6CBF9FBEA55C"><gtr:id>B7F12B52-BF14-41B7-9A90-6CBF9FBEA55C</gtr:id><gtr:title>The CRTC1-SIK1 pathway regulates entrainment of the circadian clock.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a0d31076f8584287002efea3d1eeb4f7"><gtr:id>a0d31076f8584287002efea3d1eeb4f7</gtr:id><gtr:otherNames>Jagannath A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1276BC46-4258-4CC6-8618-4688DC58F16F"><gtr:id>1276BC46-4258-4CC6-8618-4688DC58F16F</gtr:id><gtr:title>Delivery of therapeutic oligonucleotides with cell penetrating peptides.</gtr:title><gtr:parentPublicationTitle>Advanced drug delivery reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e35eaaadb1f009aa8b423537ae3b6a03"><gtr:id>e35eaaadb1f009aa8b423537ae3b6a03</gtr:id><gtr:otherNames>Boisgu?rin P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0169-409X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A4FC5C77-54AE-42ED-9F71-FCAA5DE391E6"><gtr:id>A4FC5C77-54AE-42ED-9F71-FCAA5DE391E6</gtr:id><gtr:title>Exosome-mediated delivery of siRNA in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>Nature protocols</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7f17fb92aa86d9a83bfb913a850fe197"><gtr:id>7f17fb92aa86d9a83bfb913a850fe197</gtr:id><gtr:otherNames>El-Andaloussi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1750-2799</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B99FB035-33F9-4256-ACDD-1039A8363F41"><gtr:id>B99FB035-33F9-4256-ACDD-1039A8363F41</gtr:id><gtr:title>Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b7bb9ddd1d52e8aedca258b33a5fc54b"><gtr:id>b7bb9ddd1d52e8aedca258b33a5fc54b</gtr:id><gtr:otherNames>Yin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/31598214-75E2-4912-BE13-7416D53F80D0"><gtr:id>31598214-75E2-4912-BE13-7416D53F80D0</gtr:id><gtr:title>PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d3da82a2c3555614b11f8aa0ad48d123"><gtr:id>d3da82a2c3555614b11f8aa0ad48d123</gtr:id><gtr:otherNames>Ezzat K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7DF68890-C615-419C-9E32-A950CCC0E78A"><gtr:id>7DF68890-C615-419C-9E32-A950CCC0E78A</gtr:id><gtr:title>How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/90c0247455a00e50e0d2f8876b067d92"><gtr:id>90c0247455a00e50e0d2f8876b067d92</gtr:id><gtr:otherNames>Godfrey C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F69E279B-E3A4-4657-BBAF-EABD2416D190"><gtr:id>F69E279B-E3A4-4657-BBAF-EABD2416D190</gtr:id><gtr:title>Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/657260e5076ba6423d7ba111f3b75899"><gtr:id>657260e5076ba6423d7ba111f3b75899</gtr:id><gtr:otherNames>Betts CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7D4EC8B6-77DB-4456-85A0-E70A309FDA0C"><gtr:id>7D4EC8B6-77DB-4456-85A0-E70A309FDA0C</gtr:id><gtr:title>Use of Cell-Penetrating-Peptides in Oligonucleotide Splice Switching Therapy</gtr:title><gtr:parentPublicationTitle>Current Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/162f7555df23034fd26dad0ff1f079eb"><gtr:id>162f7555df23034fd26dad0ff1f079eb</gtr:id><gtr:otherNames>A. El Andaloussi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AA4DA029-A2FC-412A-923B-15BE7872C661"><gtr:id>AA4DA029-A2FC-412A-923B-15BE7872C661</gtr:id><gtr:title>Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7ceef2a90e46a0e4368653e63abe06ba"><gtr:id>7ceef2a90e46a0e4368653e63abe06ba</gtr:id><gtr:otherNames>Malerba A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/99E44CDB-8AFF-493A-9BBE-074E3469815B"><gtr:id>99E44CDB-8AFF-493A-9BBE-074E3469815B</gtr:id><gtr:title>Tsc1 (hamartin) confers neuroprotection against ischemia by inducing autophagy.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/32765c87e5bd7e45e19409581da710ea"><gtr:id>32765c87e5bd7e45e19409581da710ea</gtr:id><gtr:otherNames>Papadakis M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C36B1177-68A3-414C-B325-5BD4C4C9852D"><gtr:id>C36B1177-68A3-414C-B325-5BD4C4C9852D</gtr:id><gtr:title>Extracellular microRNAs are dynamic non-vesicular biomarkers of muscle turnover.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a49392451d14de11f6d8a28bd0e7ceba"><gtr:id>a49392451d14de11f6d8a28bd0e7ceba</gtr:id><gtr:otherNames>Roberts TC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D5AC1FD4-2596-4D3A-ACDC-BAF642938F2F"><gtr:id>D5AC1FD4-2596-4D3A-ACDC-BAF642938F2F</gtr:id><gtr:title>RNA therapy for polyglutamine neurodegenerative diseases.</gtr:title><gtr:parentPublicationTitle>Expert reviews in molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3317ef5032b615cb7a80f92fa1019330"><gtr:id>3317ef5032b615cb7a80f92fa1019330</gtr:id><gtr:otherNames>Watson LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1462-3994</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/667A4C25-713D-4512-9141-3EDBE160C294"><gtr:id>667A4C25-713D-4512-9141-3EDBE160C294</gtr:id><gtr:title>Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e1d7d521cf31af5da03c6579f43289e8"><gtr:id>e1d7d521cf31af5da03c6579f43289e8</gtr:id><gtr:otherNames>Koo T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B76437EB-A472-4572-877B-089FC49BBA3B"><gtr:id>B76437EB-A472-4572-877B-089FC49BBA3B</gtr:id><gtr:title>Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1e42d567be93558e30e4dfe746a91cbb"><gtr:id>1e42d567be93558e30e4dfe746a91cbb</gtr:id><gtr:otherNames>Lee Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DBCB191B-8C29-4DB9-84FA-A85B28A2271C"><gtr:id>DBCB191B-8C29-4DB9-84FA-A85B28A2271C</gtr:id><gtr:title>Current understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Molecules (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d55996fff9294cf765dc18a8d6c1df5a"><gtr:id>d55996fff9294cf765dc18a8d6c1df5a</gtr:id><gtr:otherNames>van Westering TL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1420-3049</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FA32EE7A-AE4C-4A8A-A50F-859F72B19E88"><gtr:id>FA32EE7A-AE4C-4A8A-A50F-859F72B19E88</gtr:id><gtr:title>CPP-directed oligonucleotide exon skipping in animal models of Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b7bb9ddd1d52e8aedca258b33a5fc54b"><gtr:id>b7bb9ddd1d52e8aedca258b33a5fc54b</gtr:id><gtr:otherNames>Yin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B10B8816-BAB0-4802-BFC0-7A97FEECE754"><gtr:id>B10B8816-BAB0-4802-BFC0-7A97FEECE754</gtr:id><gtr:title>Assessment of RT-qPCR normalization strategies for accurate quantification of extracellular microRNAs in murine serum.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a49392451d14de11f6d8a28bd0e7ceba"><gtr:id>a49392451d14de11f6d8a28bd0e7ceba</gtr:id><gtr:otherNames>Roberts TC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3132EA77-327A-4249-871D-A6C15C984317"><gtr:id>3132EA77-327A-4249-871D-A6C15C984317</gtr:id><gtr:title>Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a49392451d14de11f6d8a28bd0e7ceba"><gtr:id>a49392451d14de11f6d8a28bd0e7ceba</gtr:id><gtr:otherNames>Roberts TC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BB1C994F-9F33-4507-A12B-6E850B106A99"><gtr:id>BB1C994F-9F33-4507-A12B-6E850B106A99</gtr:id><gtr:title>Splicing therapy for neuromuscular disease.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/326400d549146e3232c1d56a2fa18384"><gtr:id>326400d549146e3232c1d56a2fa18384</gtr:id><gtr:otherNames>Douglas AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1044-7431</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5AFA4FE8-2CE6-431E-9958-BDAFC2C7EBE6"><gtr:id>5AFA4FE8-2CE6-431E-9958-BDAFC2C7EBE6</gtr:id><gtr:title>Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/068c70e545536ea9dee784649032d44f"><gtr:id>068c70e545536ea9dee784649032d44f</gtr:id><gtr:otherNames>Bestas B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/02188713-A29E-40FA-9057-F684C9EE04B4"><gtr:id>02188713-A29E-40FA-9057-F684C9EE04B4</gtr:id><gtr:title>To skip or not to skip: that is the question for duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dfeee30751678f5126da4059b895c3ce"><gtr:id>dfeee30751678f5126da4059b895c3ce</gtr:id><gtr:otherNames>Wood MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/38EB486A-84DE-4A35-A44A-61B9BEEFC81C"><gtr:id>38EB486A-84DE-4A35-A44A-61B9BEEFC81C</gtr:id><gtr:title>Detection and quantification of extracellular microRNAs in murine biofluids.</gtr:title><gtr:parentPublicationTitle>Biological procedures online</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a49392451d14de11f6d8a28bd0e7ceba"><gtr:id>a49392451d14de11f6d8a28bd0e7ceba</gtr:id><gtr:otherNames>Roberts TC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1480-9222</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4E672697-4D64-4518-A48F-8AB6A48C76F4"><gtr:id>4E672697-4D64-4518-A48F-8AB6A48C76F4</gtr:id><gtr:title>Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f63c6b2fcac189b2b9a8f58f72925bb4"><gtr:id>f63c6b2fcac189b2b9a8f58f72925bb4</gtr:id><gtr:otherNames>Hammond SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8C2652D0-CB86-492F-AE4E-CF907FFDD3C5"><gtr:id>8C2652D0-CB86-492F-AE4E-CF907FFDD3C5</gtr:id><gtr:title>Correlating In Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified Oligonucleotides.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f63c6b2fcac189b2b9a8f58f72925bb4"><gtr:id>f63c6b2fcac189b2b9a8f58f72925bb4</gtr:id><gtr:otherNames>Hammond SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0759F150-FD1D-414B-AECE-6782C41CEBD5"><gtr:id>0759F150-FD1D-414B-AECE-6782C41CEBD5</gtr:id><gtr:title>Epigenetics and ncRNAs in brain function and disease: mechanisms and prospects for therapy.</gtr:title><gtr:parentPublicationTitle>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/66be3925904c0a5c83e4c6428c23a229"><gtr:id>66be3925904c0a5c83e4c6428c23a229</gtr:id><gtr:otherNames>Varela MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1878-7479</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/25B1C191-CC66-49B8-9AFF-C1D903190B7E"><gtr:id>25B1C191-CC66-49B8-9AFF-C1D903190B7E</gtr:id><gtr:title>Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b7bb9ddd1d52e8aedca258b33a5fc54b"><gtr:id>b7bb9ddd1d52e8aedca258b33a5fc54b</gtr:id><gtr:otherNames>Yin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6FF9A8FA-2CDD-455A-8E91-E21D5FB5A06D"><gtr:id>6FF9A8FA-2CDD-455A-8E91-E21D5FB5A06D</gtr:id><gtr:title>Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c0da86a1d1d9588103bac2e8dfffd519"><gtr:id>c0da86a1d1d9588103bac2e8dfffd519</gtr:id><gtr:otherNames>Kooijmans SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/539D109C-35B8-4ED4-A3BB-60D88438BB08"><gtr:id>539D109C-35B8-4ED4-A3BB-60D88438BB08</gtr:id><gtr:title>Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f82799396794e89283a9b0507792aa31"><gtr:id>f82799396794e89283a9b0507792aa31</gtr:id><gtr:otherNames>Ivanova GD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/91D5D67D-03A2-4DBD-A1F3-DA3C891BD1EC"><gtr:id>91D5D67D-03A2-4DBD-A1F3-DA3C891BD1EC</gtr:id><gtr:title>Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9a6cbf20c5cc231809c413715c6e77d8"><gtr:id>9a6cbf20c5cc231809c413715c6e77d8</gtr:id><gtr:otherNames>Fairclough RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-0056</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/37A13DD7-5545-46B4-8674-819C42A0C81D"><gtr:id>37A13DD7-5545-46B4-8674-819C42A0C81D</gtr:id><gtr:title>Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/657260e5076ba6423d7ba111f3b75899"><gtr:id>657260e5076ba6423d7ba111f3b75899</gtr:id><gtr:otherNames>Betts CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AE435716-5A0F-4A99-97F3-132DF0356FD6"><gtr:id>AE435716-5A0F-4A99-97F3-132DF0356FD6</gtr:id><gtr:title>Oligonucleotide therapies: the future of amyotrophic lateral sclerosis treatment?</gtr:title><gtr:parentPublicationTitle>Neurodegenerative disease management</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9518a7f05163862ae602b67902c07daf"><gtr:id>9518a7f05163862ae602b67902c07daf</gtr:id><gtr:otherNames>Aoki Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1758-2024</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4AECC570-276D-410A-8A21-4DE96149760A"><gtr:id>4AECC570-276D-410A-8A21-4DE96149760A</gtr:id><gtr:title>Identification of a novel muscle targeting peptide in mdx mice.</gtr:title><gtr:parentPublicationTitle>Peptides</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3ab632260589a58159b24c524820efc5"><gtr:id>3ab632260589a58159b24c524820efc5</gtr:id><gtr:otherNames>Seow Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0196-9781</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A23E3546-50F0-47B3-A492-91BABC75654A"><gtr:id>A23E3546-50F0-47B3-A492-91BABC75654A</gtr:id><gtr:title>Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b7bb9ddd1d52e8aedca258b33a5fc54b"><gtr:id>b7bb9ddd1d52e8aedca258b33a5fc54b</gtr:id><gtr:otherNames>Yin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ED05205D-E7F2-4DE2-B762-3E870A2B48CC"><gtr:id>ED05205D-E7F2-4DE2-B762-3E870A2B48CC</gtr:id><gtr:title>A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b7bb9ddd1d52e8aedca258b33a5fc54b"><gtr:id>b7bb9ddd1d52e8aedca258b33a5fc54b</gtr:id><gtr:otherNames>Yin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6B9D8801-AE7F-499E-851A-3F290DCE22F8"><gtr:id>6B9D8801-AE7F-499E-851A-3F290DCE22F8</gtr:id><gtr:title>Exosome nanotechnology: an emerging paradigm shift in drug delivery: exploitation of exosome nanovesicles for systemic in vivo delivery of RNAi heralds new horizons for drug delivery across biological barriers.</gtr:title><gtr:parentPublicationTitle>BioEssays : news and reviews in molecular, cellular and developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/80fb25b7d85dbde6baf7baae69ba2370"><gtr:id>80fb25b7d85dbde6baf7baae69ba2370</gtr:id><gtr:otherNames>Lakhal S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0265-9247</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9388BAA9-0869-4F67-A0CB-714438BAAE0B"><gtr:id>9388BAA9-0869-4F67-A0CB-714438BAAE0B</gtr:id><gtr:title>Extracellular vesicles: biology and emerging therapeutic opportunities.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Drug discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/711d9c529c4f9e17209ff685760132d6"><gtr:id>711d9c529c4f9e17209ff685760132d6</gtr:id><gtr:otherNames>EL Andaloussi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-1776</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BB8CECCB-D286-4BD0-B13C-262187442464"><gtr:id>BB8CECCB-D286-4BD0-B13C-262187442464</gtr:id><gtr:title>DNA cage delivery to mammalian cells.</gtr:title><gtr:parentPublicationTitle>ACS nano</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/820fc3735183b8856e820aad6615536f"><gtr:id>820fc3735183b8856e820aad6615536f</gtr:id><gtr:otherNames>Walsh AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1936-0851</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1A5905A6-5DE4-4436-A0EB-48F958DEBE3F"><gtr:id>1A5905A6-5DE4-4436-A0EB-48F958DEBE3F</gtr:id><gtr:title>Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/657260e5076ba6423d7ba111f3b75899"><gtr:id>657260e5076ba6423d7ba111f3b75899</gtr:id><gtr:otherNames>Betts CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/252523D1-2480-4B8E-9039-6F9BF5408DDA"><gtr:id>252523D1-2480-4B8E-9039-6F9BF5408DDA</gtr:id><gtr:title>Therapeutic targeting of non-coding RNAs.</gtr:title><gtr:parentPublicationTitle>Essays in biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a49392451d14de11f6d8a28bd0e7ceba"><gtr:id>a49392451d14de11f6d8a28bd0e7ceba</gtr:id><gtr:otherNames>Roberts TC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0071-1365</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EAC3FA9B-5DA1-43A4-9F50-3984E49D7DC7"><gtr:id>EAC3FA9B-5DA1-43A4-9F50-3984E49D7DC7</gtr:id><gtr:title>Cells release subpopulations of exosomes with distinct molecular and biological properties.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dbdbc7fc0a89cf4b831d00fce7b1cf84"><gtr:id>dbdbc7fc0a89cf4b831d00fce7b1cf84</gtr:id><gtr:otherNames>Willms E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ECB31C72-1192-4DCB-9E4C-BB1EF887D6D3"><gtr:id>ECB31C72-1192-4DCB-9E4C-BB1EF887D6D3</gtr:id><gtr:title>Identification of allele-specific RNAi effectors targeting genetic forms of Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3fd4c93bcc6764bb4a77247fb6ebec34"><gtr:id>3fd4c93bcc6764bb4a77247fb6ebec34</gtr:id><gtr:otherNames>Sibley CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A98BB571-44FD-402B-859C-7906B38BD030"><gtr:id>A98BB571-44FD-402B-859C-7906B38BD030</gtr:id><gtr:title>Mirtrons, an emerging class of atypical miRNA.</gtr:title><gtr:parentPublicationTitle>Wiley interdisciplinary reviews. RNA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9e6264163766fda901e87addaa6eedb1"><gtr:id>9e6264163766fda901e87addaa6eedb1</gtr:id><gtr:otherNames>Curtis HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1757-7004</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6659925D-E141-4B5E-95BD-0F4ADD739614"><gtr:id>6659925D-E141-4B5E-95BD-0F4ADD739614</gtr:id><gtr:title>How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/90c0247455a00e50e0d2f8876b067d92"><gtr:id>90c0247455a00e50e0d2f8876b067d92</gtr:id><gtr:otherNames>Godfrey C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5B4D14CE-AC7F-4A46-8DA8-A69ECF75FEC5"><gtr:id>5B4D14CE-AC7F-4A46-8DA8-A69ECF75FEC5</gtr:id><gtr:title>Optimizing tissue-specific antisense oligonucleotide-peptide conjugates.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/657260e5076ba6423d7ba111f3b75899"><gtr:id>657260e5076ba6423d7ba111f3b75899</gtr:id><gtr:otherNames>Betts CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/126160E1-8977-4152-8357-FAD810FB1842"><gtr:id>126160E1-8977-4152-8357-FAD810FB1842</gtr:id><gtr:title>The biogenesis and characterization of mammalian microRNAs of mirtron origin.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3fd4c93bcc6764bb4a77247fb6ebec34"><gtr:id>3fd4c93bcc6764bb4a77247fb6ebec34</gtr:id><gtr:otherNames>Sibley CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2C0F7C55-45AE-490F-BDEE-7336D1A29DC4"><gtr:id>2C0F7C55-45AE-490F-BDEE-7336D1A29DC4</gtr:id><gtr:title>Silencing of Parkinson's disease-associated genes with artificial mirtron mimics of miR-1224.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3fd4c93bcc6764bb4a77247fb6ebec34"><gtr:id>3fd4c93bcc6764bb4a77247fb6ebec34</gtr:id><gtr:otherNames>Sibley CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/40409DAA-57D3-41D8-B03D-8F4F2C312413"><gtr:id>40409DAA-57D3-41D8-B03D-8F4F2C312413</gtr:id><gtr:title>Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-a2 chain-null congenital muscular dystrophy mice.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9518a7f05163862ae602b67902c07daf"><gtr:id>9518a7f05163862ae602b67902c07daf</gtr:id><gtr:otherNames>Aoki Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/52903686-3A2E-4D40-BD7B-E96AFF961F9A"><gtr:id>52903686-3A2E-4D40-BD7B-E96AFF961F9A</gtr:id><gtr:title>Targeting RNA to treat neuromuscular disease.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Drug discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d12a81c1a41c39038e9286100f8688e7"><gtr:id>d12a81c1a41c39038e9286100f8688e7</gtr:id><gtr:otherNames>Muntoni F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1474-1776</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/861D78F8-FB61-44B5-AF80-6AED703C3C3E"><gtr:id>861D78F8-FB61-44B5-AF80-6AED703C3C3E</gtr:id><gtr:title>An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies.</gtr:title><gtr:parentPublicationTitle>Current opinion in pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5b27c6dc93317065f02b0cbdba1e0eda"><gtr:id>5b27c6dc93317065f02b0cbdba1e0eda</gtr:id><gtr:otherNames>McClorey G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-4892</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/66912784-C1AD-45D6-AFBC-F1FF18AED7E1"><gtr:id>66912784-C1AD-45D6-AFBC-F1FF18AED7E1</gtr:id><gtr:title>Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/079cb700d5d8d3f1571cdabcb383b5d3"><gtr:id>079cb700d5d8d3f1571cdabcb383b5d3</gtr:id><gtr:otherNames>Shabanpoor F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C16F4089-62CC-4041-A3FE-D3F67F1EED2F"><gtr:id>C16F4089-62CC-4041-A3FE-D3F67F1EED2F</gtr:id><gtr:title>Development of multiexon skipping antisense oligonucleotide therapy for Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>BioMed research international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9518a7f05163862ae602b67902c07daf"><gtr:id>9518a7f05163862ae602b67902c07daf</gtr:id><gtr:otherNames>Aoki Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8A2CBF39-B2E6-49A3-9B6A-9282BB6E47F7"><gtr:id>8A2CBF39-B2E6-49A3-9B6A-9282BB6E47F7</gtr:id><gtr:title>Context Dependent Effects of Chimeric Peptide Morpholino Conjugates Contribute to Dystrophin Exon-skipping Efficiency.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b7bb9ddd1d52e8aedca258b33a5fc54b"><gtr:id>b7bb9ddd1d52e8aedca258b33a5fc54b</gtr:id><gtr:otherNames>Yin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2095DF4E-3D7C-4C93-969A-C46896BB3237"><gtr:id>2095DF4E-3D7C-4C93-969A-C46896BB3237</gtr:id><gtr:title>Isoforms of Melanopsin Mediate Different Behavioral Responses to Light.</gtr:title><gtr:parentPublicationTitle>Current biology : CB</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a0d31076f8584287002efea3d1eeb4f7"><gtr:id>a0d31076f8584287002efea3d1eeb4f7</gtr:id><gtr:otherNames>Jagannath A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-9822</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/68C4F34D-5FE9-436B-A91E-705D6DBDF72D"><gtr:id>68C4F34D-5FE9-436B-A91E-705D6DBDF72D</gtr:id><gtr:title>Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5dcceb96c14ac16b6386b86215cac484"><gtr:id>5dcceb96c14ac16b6386b86215cac484</gtr:id><gtr:otherNames>Betts C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5D0E51B7-1C1B-42AA-A6A9-C98444DFF403"><gtr:id>5D0E51B7-1C1B-42AA-A6A9-C98444DFF403</gtr:id><gtr:title>Natural Antisense Makes Sense for Gene-specific Activation in Brain.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/66be3925904c0a5c83e4c6428c23a229"><gtr:id>66be3925904c0a5c83e4c6428c23a229</gtr:id><gtr:otherNames>Varela MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1549B209-A7B8-4058-909A-2AF4EBC3EB66"><gtr:id>1549B209-A7B8-4058-909A-2AF4EBC3EB66</gtr:id><gtr:title>Small RNA-Mediated Epigenetic Myostatin Silencing.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a49392451d14de11f6d8a28bd0e7ceba"><gtr:id>a49392451d14de11f6d8a28bd0e7ceba</gtr:id><gtr:otherNames>Roberts TC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F632CE76-6432-4769-90D1-17F540202547"><gtr:id>F632CE76-6432-4769-90D1-17F540202547</gtr:id><gtr:title>Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes.</gtr:title><gtr:parentPublicationTitle>Nature biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f7322e4d45d8d897e3ce8b1d90bde79b"><gtr:id>f7322e4d45d8d897e3ce8b1d90bde79b</gtr:id><gtr:otherNames>Alvarez-Erviti L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1087-0156</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4BD8766E-5874-4FF8-920F-6384FA03C1EA"><gtr:id>4BD8766E-5874-4FF8-920F-6384FA03C1EA</gtr:id><gtr:title>Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/87b7c33c156654dd0239fa815b9f9607"><gtr:id>87b7c33c156654dd0239fa815b9f9607</gtr:id><gtr:otherNames>Rouillon J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/41B59E96-26A0-4ECF-9844-23658A95EF0F"><gtr:id>41B59E96-26A0-4ECF-9844-23658A95EF0F</gtr:id><gtr:title>Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5dcceb96c14ac16b6386b86215cac484"><gtr:id>5dcceb96c14ac16b6386b86215cac484</gtr:id><gtr:otherNames>Betts C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D690AF7D-942D-4A09-A8F2-4311A8152D62"><gtr:id>D690AF7D-942D-4A09-A8F2-4311A8152D62</gtr:id><gtr:title>Use of cell-penetrating-peptides in oligonucleotide splice switching therapy.</gtr:title><gtr:parentPublicationTitle>Current gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4feda229b3bfd862a06923a239c0de16"><gtr:id>4feda229b3bfd862a06923a239c0de16</gtr:id><gtr:otherNames>El Andaloussi SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1566-5232</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/865DEC55-8992-493F-BE74-D1F29D6ECA96"><gtr:id>865DEC55-8992-493F-BE74-D1F29D6ECA96</gtr:id><gtr:title>Diaphragm rescue alone prevents heart dysfunction in dystrophic mice.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/321e063cceeeaa3dbaebdbfe5918c9c4"><gtr:id>321e063cceeeaa3dbaebdbfe5918c9c4</gtr:id><gtr:otherNames>Crisp A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0DB5B2C8-3309-4758-AB59-63D04C4F94F9"><gtr:id>0DB5B2C8-3309-4758-AB59-63D04C4F94F9</gtr:id><gtr:title>Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6a72e72c868a57ce5d3014d80ac1ce8a"><gtr:id>6a72e72c868a57ce5d3014d80ac1ce8a</gtr:id><gtr:otherNames>van Dommelen SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AFFC3A46-77E3-4B55-87B7-9D5C56F86D09"><gtr:id>AFFC3A46-77E3-4B55-87B7-9D5C56F86D09</gtr:id><gtr:title>Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/41bda94ef4fcc68a41437c11403d7f83"><gtr:id>41bda94ef4fcc68a41437c11403d7f83</gtr:id><gtr:otherNames>Goyenvalle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/79C2B5B0-F721-4FBB-B5E9-5087771A6FD5"><gtr:id>79C2B5B0-F721-4FBB-B5E9-5087771A6FD5</gtr:id><gtr:title>Cell penetrating peptide delivery of splice directing oligonucleotides as a treatment for Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Current pharmaceutical design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/657260e5076ba6423d7ba111f3b75899"><gtr:id>657260e5076ba6423d7ba111f3b75899</gtr:id><gtr:otherNames>Betts CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1381-6128</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D5762448-BEA0-4246-8851-6791D0828973"><gtr:id>D5762448-BEA0-4246-8851-6791D0828973</gtr:id><gtr:title>Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e5cbf7dc26a737e3b68f235e753a64e8"><gtr:id>e5cbf7dc26a737e3b68f235e753a64e8</gtr:id><gtr:otherNames>J?rver P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D4BC135F-9A1B-432F-B5F2-0E173C35A5EA"><gtr:id>D4BC135F-9A1B-432F-B5F2-0E173C35A5EA</gtr:id><gtr:title>Artificial mirtron-mediated gene knockdown: functional DMPK silencing in mammalian cells.</gtr:title><gtr:parentPublicationTitle>RNA (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3ab632260589a58159b24c524820efc5"><gtr:id>3ab632260589a58159b24c524820efc5</gtr:id><gtr:otherNames>Seow Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1355-8382</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EE76C462-F188-4190-A37A-388708E2527C"><gtr:id>EE76C462-F188-4190-A37A-388708E2527C</gtr:id><gtr:title>Design and application of bispecific splice-switching oligonucleotides.</gtr:title><gtr:parentPublicationTitle>Nucleic acid therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/068c70e545536ea9dee784649032d44f"><gtr:id>068c70e545536ea9dee784649032d44f</gtr:id><gtr:otherNames>Bestas B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2159-3337</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0149CD70-786F-4E9B-A52F-45E650A53A96"><gtr:id>0149CD70-786F-4E9B-A52F-45E650A53A96</gtr:id><gtr:title>Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a49392451d14de11f6d8a28bd0e7ceba"><gtr:id>a49392451d14de11f6d8a28bd0e7ceba</gtr:id><gtr:otherNames>Roberts TC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/90859E54-4989-494A-82D4-DFD7A5FCED70"><gtr:id>90859E54-4989-494A-82D4-DFD7A5FCED70</gtr:id><gtr:title>Exosomes and the blood-brain barrier: implications for neurological diseases.</gtr:title><gtr:parentPublicationTitle>Therapeutic delivery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dfeee30751678f5126da4059b895c3ce"><gtr:id>dfeee30751678f5126da4059b895c3ce</gtr:id><gtr:otherNames>Wood MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2041-5990</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/03BC7C92-8219-4B3D-9675-47C8F76B66A0"><gtr:id>03BC7C92-8219-4B3D-9675-47C8F76B66A0</gtr:id><gtr:title>In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>The journal of gene medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/85103be6c0a7ff70942dad56b4330959"><gtr:id>85103be6c0a7ff70942dad56b4330959</gtr:id><gtr:otherNames>Wang Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1099-498X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B26F880F-770F-45ED-A635-4C96EE6106EF"><gtr:id>B26F880F-770F-45ED-A635-4C96EE6106EF</gtr:id><gtr:title>Peptide nanoparticle delivery of charge-neutral splice-switching morpholino oligonucleotides.</gtr:title><gtr:parentPublicationTitle>Nucleic acid therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e5cbf7dc26a737e3b68f235e753a64e8"><gtr:id>e5cbf7dc26a737e3b68f235e753a64e8</gtr:id><gtr:otherNames>J?rver P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2159-3337</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/38C66907-8B21-4E21-833E-3EC0996159EB"><gtr:id>38C66907-8B21-4E21-833E-3EC0996159EB</gtr:id><gtr:title>Intranasal exosomes for treatment of neuroinflammation? Prospects and limitations.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/80fb25b7d85dbde6baf7baae69ba2370"><gtr:id>80fb25b7d85dbde6baf7baae69ba2370</gtr:id><gtr:otherNames>Lakhal S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7DFFCD1D-AAA1-4ECA-950F-63C31F03D5AE"><gtr:id>7DFFCD1D-AAA1-4ECA-950F-63C31F03D5AE</gtr:id><gtr:title>Oligonucleotide-Based Therapy for FTD/ALS Caused by the C9orf72 Repeat Expansion: A Perspective.</gtr:title><gtr:parentPublicationTitle>Journal of nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5fbd57cbed236dc1fcaf8d7b82dea9c6"><gtr:id>5fbd57cbed236dc1fcaf8d7b82dea9c6</gtr:id><gtr:otherNames>Fernandes SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2090-0201</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/26862A9A-CD78-45A3-931B-A3CC47B97EB2"><gtr:id>26862A9A-CD78-45A3-931B-A3CC47B97EB2</gtr:id><gtr:title>Correlating In Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified Oligonucleotides.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f63c6b2fcac189b2b9a8f58f72925bb4"><gtr:id>f63c6b2fcac189b2b9a8f58f72925bb4</gtr:id><gtr:otherNames>Hammond SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/58061215-E29C-4230-BF87-8E65EA39AE28"><gtr:id>58061215-E29C-4230-BF87-8E65EA39AE28</gtr:id><gtr:title>Exosomes and the emerging field of exosome-based gene therapy.</gtr:title><gtr:parentPublicationTitle>Current gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1c9de79e5be38ffc7623ce13696802cd"><gtr:id>1c9de79e5be38ffc7623ce13696802cd</gtr:id><gtr:otherNames>O'Loughlin AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1566-5232</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6E9C7524-CEAA-41A4-A581-EB4C0DD595C1"><gtr:id>6E9C7524-CEAA-41A4-A581-EB4C0DD595C1</gtr:id><gtr:title>Self-Assembly into Nanoparticles Is Essential for Receptor Mediated Uptake of Therapeutic Antisense Oligonucleotides.</gtr:title><gtr:parentPublicationTitle>Nano letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d3da82a2c3555614b11f8aa0ad48d123"><gtr:id>d3da82a2c3555614b11f8aa0ad48d123</gtr:id><gtr:otherNames>Ezzat K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1530-6984</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900887</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>